"Good Medicine" 3 varieties of the first review; Omeprazole into the third batch of collection; Zhengda Qing and Howson had the first imitation of the competition products were accepted ...

Guide Read: Good Medicine To See Consistency Evaluation Week Dynamics! As of July 10, CDE has received 2202 consistency evaluation numbers (526 varieties of 580 enterprises, according to supplementary applications, the same below), and has received 603 acceptance numbers!----this week (July 3 to July 10) and three more varieties were the first to be evaluated, 35 varieties were awarded, Zhengda Qing and Howson had the first imitation of the competition productsthe details of the first evaluation of 3 varieties, the third batch of collection products in the list this week there are 3 varieties of the first through consistency evaluation, respectively, Shandong New Era of Omeprazole intestinal tablets, China Resources Purple Bamboo Pharmaceuticals miso prostoster tablets, LunanBert Pharmaceutical's oxalic acid Mosabili tabletsthis week's consistency evaluation of the details of the table omeprazole intestinal lysoper omeprazole is a proton pump inhibitor, clinically used in the stomach, duodenum ulcers, reflux esophagitis, zhuo-Ai syndrome treatmentDeveloped by AstraZeneca,Omeprazole was first listed in Switzerland in 1988, in the United States in 1989, and then in other European countries and Japanthe original research manufacturers without intestinal solution tabletsit is understood that omeprazole was once the world's heavyweight varieties, the market matures, pharmaceutical intelligence data enterprise version of hospital sales statistics, Omeprazole 2019 sample hospital sales of 260 million yuanfrom the dosage form, intestinal-soluble capsules accounted for the largest proportion, followed by tablets, from the enterprise point of view, Changzhou four drugs, Cornbey, Shandong New Era Pharmaceutical Market share ranked in the top threeomeprazole oral dosage form consistency evaluation is a highly difficult variety, according to the drug registration and acceptance database shows that up to now, Omeprazole intestinal tablets Shandong New Era Pharmaceutical seisido is the first enterprise to pass the drug consistency evaluationit is worth mentioning that in the network spread of the country's third batch of 53 varieties of 86 standards of the centralized procurement catalog, Omeprazole oral frequently released agent type in the column, in the third batch of collection is about to start the threshold, Shandong New Era Pharmaceutical Omeprazole tablets the first through consistency evaluation, successfully shortlisted for the collectionmisoprostol tabletmisoprostol is a prostaglandin E1 analogue, mainly used for the prevention and treatment of stomach and duodenal ulcers, developed by Searle (now Pfizer) in 1973, and its tablets were first licensed to market in 1984According to pharmaceutical data, missoprostol tablets 2019 domestic sample hospital sales data of 12.527 million yuan, of which China Resources Zizhu Pharmaceutical industry accounted for 47.08 percent, Hubei Gedian Peoplefu Pharmaceuticals accounted for 26.28 percent, as shown in the figure: the current domestic enterprises only Zhejiang Xianyu Pharmaceuticals, Shanghai Xinhua Union Pharmaceuticals, Hubei Gedian People Fu Pharmaceuticals and China Resources Zizhu Pharmaceuticals 4 enterprises have 4 market approvals, three of which have been declared for acceptance of the consistency evaluation of the variety, the first of the varieties of China Resources Zizhu Pharmaceuticals, or will further enhance product competitivenessmosabili tabletmothine mosabili is a selective 5-serotonin 4 (5-HT4) receptor agonist, clinically used for functional indigestion, esophagus reflux, gastric palsy, constipation and other treatmentsthe original research enterprise for Sumitomo Pharmaceuticalssales of moshabili tablet hospital sales in 2019 was RMB123 million, with Lunanbet having a market share of 44.84 percent at present, the acid Moshabili tablets only Yabao Pharmaceuticals, Haussen Pharmaceuticals, Chengdu Kanghong Pharmaceuticals, Lunanbet Pharmaceuticals, Guangdong Anno Pharmaceuticals 5 enterprises have 5 market approvals one of the Luunanbet Pharmaceuticals and Chengdu Kanghong Pharmaceuticaltwo two enterprises declared consistency evaluation was accepted, now Lunanbet Pharmaceuticals first passed the drug, further enhance the competitive strength of the product, in the next collection of whether it can shine, we wait and see declaration acceptance of 35 products were accepted, Zhengda day and heavy anti-spitting new drugs were hosted this week CDE new 47 acceptance number (35 varieties), from the State Drug Administration officially announced the implementation of consistency evaluation work, injection consistency evaluation declaration acceptance further speed up, this week CDE acceptance of the consistency evaluation acceptance number, according to the dosage form of nearly 75% of the injection stakes, there are 35 varieties of 23 in addition, it is worth noting that a number of varieties for this week's first declaration of consistency evaluation of the drug accepted, Zhengda Qing, Qilu Pharmaceuticals, Huaren Pharmaceuticals and other enterprises ranked among the heavy varieties of the first consistency evaluation details to be accepted this week, notably the injection of fusapitin dofamine fusapitin biglutaminamine is a NK1 receptor antagonic, developed by Mersadon (MSD), is a phosphate pre-drug of Aripitan, injected in the body quickly converted into Aripitan, initially approved in the European Union on 10 January 2008, and then in the United States, Japan has been approved, the original research drug is not yet listed in the domestic market, but last year Haussen Pharmaceuticals and The Day qing According to drug data, the injection of fusapitin dipamine is declared in September 2015 according to 3.1 new drugs, after 722 clinical on-site verification, in September 2017 into the priority review, after three rounds of additional information, was approved for listing in October 2019 last year' positive day clear injection with Fusapitan double-portuguese metformin behind howson pharmaceutical seision approved, is now the first to declare consistency evaluation, whether can reverse the first imitation of how Hawthorn enough to be robbed, it is worth looking forward to attached: This week's consistency evaluation declaration acceptance details table note: red font for this week's first declaration accepted varieties of data sources: drug intelligence data, enterprise announcements and other network public data sources: drug intelligence network, enterprise announcements and other network public information.